A prior meta-analysis of seven studies, four of which were analyzed by Pasta et al., showed a similar reduction in hepatocellular carcinoma risk in GLP-1R agonist users with T2D compared with those using insulin or other antihyperglycemic drugs (61). This evidence concerns the gene GLP1R and hepatocellular carcinoma.